Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal fourth quarter ended March 31 was ¥50.59 per share, a gain of 77.9% from ¥28.43 per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥176.3 million, a gain of 55.8% from ¥113.1 million in the prior-year period.
The normalized profit margin climbed to 3.9% from 2.8% in the year-earlier period.
Total revenue increased 10.7% year over year to ¥4.51 billion from ¥4.08 billion, and total operating expenses grew 8.6% year over year to ¥4.24 billion from ¥3.90 billion.
Reported net income rose from the prior-year period to ¥205.0 million, or ¥58.84 per share, from ¥56.0 million, or ¥14.07 per share.
For the year, the company's normalized net income totaled ¥147.24 per share, compared with ¥146.39 per share in the prior year.
Normalized net income was ¥559.4 million, a decline from ¥582.5 million in the prior year.
Full-year total revenue rose from the prior-year period to ¥17.17 billion from ¥16.55 billion, and total operating expenses grew year over year to ¥16.30 billion from ¥15.64 billion.
The company said reported net income grew 16.2% on an annual basis to ¥573.0 million, or ¥150.83 per share, in the full year, from ¥493.0 million, or ¥123.90 per share.
As of June 26, US$1 was equivalent to ¥123.96.